Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!  Twitter 
  Google+ 
Subscribe to our channel on YouTube!  YouTube  


Print  

Foundation Announces $37.7 Million Expanded Collaboration with EPIX Pharmaceuticals

April 7, 2008

Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the CF Foundation, announced today an expanded collaboration with EPIX Pharmaceuticals, Inc., to develop drugs for CF worth up $37.7 million.

The Foundation extended the collaboration following EPIX’s successful development of a computerized 3-D model of the full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR), the key protein associated with cystic fibrosis. The new agreement with EPIX, a company focused on discovering and developing novel therapeutics, brings the total size of the collaboration to more than $50 million.

EPIX scientists are now using the CFTR model to identify sites within the Delta F508 mutation of CFTR—the most common mutation in CF patients—which may be good targets for treatment. The Foundation is working with EPIX to discover drug candidates that may work on those sites and possibly restore function to the mutated CFTR protein.

“This is an expansion of a very important and productive alliance to develop new drugs to treat the core defect in cystic fibrosis,” said Robert J. Beall, Ph.D., president and chief executive officer of the Cystic Fibrosis Foundation. “EPIX has exceeded our expectations to date, and we look forward to their efforts to use unique structure-based technologies to identify molecules that may correct the faulty protein in CF—and potentially create new therapies for CF.” 

Read the full press release.

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.